Literature DB >> 26130252

Dietary γ-Tocopherol-Rich Mixture Inhibits Estrogen-Induced Mammary Tumorigenesis by Modulating Estrogen Metabolism, Antioxidant Response, and PPARγ.

Soumyasri Das Gupta1, Sudathip Sae-tan1, Joseph Wahler1, Jae Young So1, Min Ji Bak1, Larry C Cheng1, Mao-Jung Lee1, Yong Lin2, Weichung Joe Shih2, James D Shull3, Stephen Safe4, Chung S Yang5, Nanjoo Suh6.   

Abstract

This study evaluated the anticancer activity and mechanism of action of a γ-tocopherol-rich tocopherol mixture, γ-TmT, in two different animal models of estrogen-induced breast cancer. The chemopreventive effect of γ-TmT at early (6 weeks), intermediate (18 weeks), and late (31 weeks) stages of mammary tumorigenesis was determined using the August-Copenhagen Irish rat model. Female rats receiving 17β-estradiol (E2) implants were administered with different doses (0%, 0.05%, 0.1%, 0.3%, and 0.5%) of γ-TmT diet. Treatment with 0.3% and 0.5% γ-TmT decreased tumor volume and multiplicity. At 31 weeks, serum concentrations of E2 were significantly decreased by γ-TmT. γ-TmT preferentially induced expression of the E2-metabolizing enzyme CYP1A1, over CYP1B1 in the rat mammary tissues. Nrf2-dependent antioxidant response was stimulated by γ-TmT, as evident from enhanced expression of its downstream targets, NQO1, GCLM, and HMOX1. Serum concentrations of the oxidative stress marker, 8-isoprostane, were also decreased in the γ-TmT-treated groups. Treatment with γ-TmT increased expression of PPARγ and its downstream genes, PTEN and p27, whereas the cell proliferation marker, PCNA, was significantly reduced in γ-TmT-treated mammary tumors. In an orthotopic model in which human MCF-7 breast cancer cells were injected into the mammary fat pad of immunodeficient mice, γ-TmT inhibited E2-dependent tumor growth at all the doses tested. In conclusion, γ-TmT reduced mammary tumor development, in part through decreased E2 availability and reduced oxidative stress in mammary tissues; γ-TmT could thus be an effective agent for the prevention and treatment of E2-induced breast cancer. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26130252      PMCID: PMC4560648          DOI: 10.1158/1940-6207.CAPR-15-0154

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  50 in total

Review 1.  Estrogen carcinogenesis in breast cancer.

Authors:  James D Yager; Nancy E Davidson
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

Review 2.  NRF2 and cancer: the good, the bad and the importance of context.

Authors:  Michael B Sporn; Karen T Liby
Journal:  Nat Rev Cancer       Date:  2012-07-19       Impact factor: 60.716

3.  Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.

Authors:  I-Min Lee; Nancy R Cook; J Michael Gaziano; David Gordon; Paul M Ridker; Joann E Manson; Charles H Hennekens; Julie E Buring
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

4.  Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells.

Authors:  Un-Ho Jin; Syng-ook Lee; Stephen Safe
Journal:  J Pharmacol Exp Ther       Date:  2012-08-09       Impact factor: 4.030

5.  The effects of steroidal estrogens in ACI rat mammary carcinogenesis: 17beta-estradiol, 2-hydroxyestradiol, 4-hydroxyestradiol, 16alpha-hydroxyestradiol, and 4-hydroxyestrone.

Authors:  V K Turan; R I Sanchez; J J Li; S A Li; K R Reuhl; P E Thomas; A H Conney; M A Gallo; F C Kauffman; S Mesia-Vela
Journal:  J Endocrinol       Date:  2004-10       Impact factor: 4.286

6.  Supplementation with mixed tocopherols increases serum and blood cell gamma-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes.

Authors:  Michael W Clarke; Natalie C Ward; Jason H Y Wu; Jonathan M Hodgson; Ian B Puddey; Kevin D Croft
Journal:  Am J Clin Nutr       Date:  2006-01       Impact factor: 7.045

Review 7.  Does vitamin E prevent or promote cancer?

Authors:  Chung S Yang; Nanjoo Suh; Ah-Ng Tony Kong
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-03

8.  Dietary administration of δ- and γ-tocopherol inhibits tumorigenesis in the animal model of estrogen receptor-positive, but not HER-2 breast cancer.

Authors:  Amanda K Smolarek; Jae Young So; Brenda Burgess; Ah-Ng Tony Kong; Kenneth Reuhl; Yong Lin; Weichung Joe Shih; Guangxun Li; Mao-Jung Lee; Yu-Kuo Chen; Chung S Yang; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2012-09-10

Review 9.  The natural history of hormone receptor-positive breast cancer.

Authors:  Elgene Lim; Otto Metzger-Filho; Eric P Winer
Journal:  Oncology (Williston Park)       Date:  2012-08       Impact factor: 2.990

10.  Serum α-tocopherol and γ-tocopherol concentrations and prostate cancer risk in the PLCO Screening Trial: a nested case-control study.

Authors:  Stephanie J Weinstein; Ulrike Peters; Jiyoung Ahn; Marlin D Friesen; Elio Riboli; Richard B Hayes; Demetrius Albanes
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

View more
  19 in total

Review 1.  Tocopherols in cancer: An update.

Authors:  Soumyasri Das Gupta; Nanjoo Suh
Journal:  Mol Nutr Food Res       Date:  2016-02-02       Impact factor: 5.914

Review 2.  Natural Forms of Vitamin E as Effective Agents for Cancer Prevention and Therapy.

Authors:  Qing Jiang
Journal:  Adv Nutr       Date:  2017-11-15       Impact factor: 8.701

3.  Inhibitory Effects of γ- and δ-Tocopherols on Estrogen-Stimulated Breast Cancer In Vitro and In Vivo.

Authors:  Min Ji Bak; Soumyasri Das Gupta; Joseph Wahler; Hong Jin Lee; Xiaowei Li; Mao-Jung Lee; Chung S Yang; Nanjoo Suh
Journal:  Cancer Prev Res (Phila)       Date:  2017-01-17

Review 4.  Vitamin E and cancer prevention: Studies with different forms of tocopherols and tocotrienols.

Authors:  Chung S Yang; Philip Luo; Zishuo Zeng; Hong Wang; Mokenge Malafa; Nanjoo Suh
Journal:  Mol Carcinog       Date:  2020-02-03       Impact factor: 4.784

5.  δ-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice.

Authors:  Hong Wang; Xu Yang; Anna Liu; Guocan Wang; Maarten C Bosland; Chung S Yang
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

Review 6.  Role of dietary bioactive natural products in estrogen receptor-positive breast cancer.

Authors:  Min Ji Bak; Soumyasri Das Gupta; Joseph Wahler; Nanjoo Suh
Journal:  Semin Cancer Biol       Date:  2016-03-22       Impact factor: 15.707

Review 7.  Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents.

Authors:  Chung S Yang; Jayson X Chen; Hong Wang; Justin Lim
Journal:  Mol Nutr Food Res       Date:  2016-05-09       Impact factor: 5.914

8.  Tocopherols inhibit esophageal carcinogenesis through attenuating NF-κB activation and CXCR3-mediated inflammation.

Authors:  Hui Yang; Miao Xu; Fang Lu; Qiannan Zhang; Yongquan Feng; Chung S Yang; Ning Li; Xudong Jia
Journal:  Oncogene       Date:  2018-04-17       Impact factor: 9.867

9.  miR-148a Suppresses estrogen-induced viability and migration of breast cancer cells via inhibition of estrogen receptor α expression.

Authors:  Fang Ma; Yeqian Feng; Weihui Li; Zexuan Li; Tiebang Liu; Lingjiang Li
Journal:  Exp Ther Med       Date:  2017-03-22       Impact factor: 2.447

Review 10.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.